Multidisciplinary Approaches to Paraneoplastic LEMS: Insights for Healthcare Decision-Makers : Episode 3
Opinion
Video
The Clinical and Economic Impact of LEMS in SCLC Care
Author(s):
Key Takeaways
- Disparities in healthcare access can lead to delayed diagnosis and suboptimal treatment of LEMS in small cell lung cancer patients, affecting outcomes.
- Quantifying the economic burden of LEMS requires evaluating direct medical costs, indirect costs, and patient out-of-pocket expenses.
A medical expert discusses how disparities in health care access affect the management and outcomes of Lambert-Eaton myasthenic syndrome (LEMS) in patients with small cell lung cancer, how health care providers can quantify the economic burden of LEMS on both patients and health care systems, the role of patient-reported outcomes in providing deeper insights into the clinical and economic burden of LEMS, and how health systems can utilize real-world data to better understand the indirect costs of LEMS.
Video content above is prompted by the following:
- How do disparities in health care access affect the management and outcomes of Lambert-Eaton myasthenic syndrome (LEMS) in patients with small cell lung cancer?
- How can health care providers quantify the economic burden of LEMS on both patients and health care systems?
- In what ways can patient-reported outcomes provide deeper insights into the clinical and economic burden of LEMS?
- How can health systems utilize real-world data to better understand the indirect costs of LEMS?
Related Videos
Related Content
